Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +35.91%
#2 Siren Siren +30.45%
#3 Purr Purr +28.61%
#4 OriginTrail OriginTrail +25.26%
#5 UnifAI Network UnifAI Network +16.95%
#6 ApeX ApeX +15.83%
#7 龙虾 (Lobster) 龙虾 (Lobster) +15.52%
#8 Morpho Morpho +14.85%
#9 Wrapped XPL Wrapped XPL +14.62%
#10 DigiByte DigiByte +14.48%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Rangering i aksjer #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Aksjekurs
$50.82
Sist synkronisert: 2026-08-11
Markedsverdi
$102.09M
Endring (1 dag)
1.90%
Endring (1 år)
-
Land
US
Handel Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Kategori

Healthcare
P/S-forhold for Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
P/S-forhold per 2026 TTM: 0
Ifølge Hemab Therapeutics Holdings, Inc. Common Stock sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Hemab Therapeutics Holdings, Inc. Common Stock fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH